8/23/2007

The FDA has postponed completing a review of ZymoGenetics' blood-clotting drug Thrombin so it can further examine manufacturing data, the company announced. The review now is expected to be completed by Jan. 17 of next year.

Full Story:
SeattlePI.com

Related Summaries